HER-096 shows promise in Parkinson's study with first healthy volunteer dosed.

Herantis Pharma has dosed the first healthy volunteer in a Phase 1a clinical trial of HER-096, a treatment candidate for Parkinson's disease. The trial will evaluate the safety and efficacy of HER-096, which is designed to retain the biological activity of cerebral dopamine neurotrophic factor (CDNF), a protein with neuroprotective properties. The company expects to obtain topline data by the end of the year.